Abivax

Contributing Author

Recent Articles by Abivax

Jul-06	Abivax Announces Closing of $920 Million Public Offering ABVX GlobeNewswire
Jul-02	Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (807M) ABVX +9.12% GlobeNewswire
Jul-01	Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (702M) Public Offering of American Depositary Shares ABVX GlobeNewswire
Jul-01	Abivax announces trading resumption of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jul-01	Abivax Announces Pricing of Oversubscribed and Upsized $800M (702M) Public Offering of American Depositary Shares ABVX GlobeNewswire
Jul-01	Abivax announces temporary trading halt of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jun-30	Abivax Announces Launch of Public Offering of American Depositary Shares ABVX +38.60% GlobeNewswire
Jun-29	Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database ABVX GlobeNewswire
Jun-01	Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis ABVX ABVX -44.10% GlobeNewswire
May-22	Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis ABVX GlobeNewswire
May-11	Abivax Announces Results of its May 11, 2026 Annual General Meeting ABVX GlobeNewswire
May-05	Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (38.5M) Offering of American Depositary Shares ABVX +5.68% GlobeNewswire
Apr-22	Abivax to Present Data on Obefazimod at Digestive Disease Week ABVX GlobeNewswire
Apr-20	Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents ABVX GlobeNewswire
Apr-01	Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies ABVX GlobeNewswire
Mar-23	Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABVX GlobeNewswire
Feb-21	Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 ABVX GlobeNewswire
Jan-07	Abivax Provides 2026 Corporate Outlook ABVX +6.20% ABVX -8.69% GlobeNewswire
Dec-18	Abivax to be Added to Nasdaq Biotechnology Index ABVX GlobeNewswire
Dec-17	Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings ABVX GlobeNewswire
Dec-15	Abivax Presents Third Quarter 2025 Financial Results ABVX -6.08% ABVX -5.88% GlobeNewswire
Nov-03	Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis ABVX GlobeNewswire
Oct-06	Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies ABVX GlobeNewswire
Oct-05	Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data ABVX GlobeNewswire
Sep-29	Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting ABVX GlobeNewswire
Sep-23	Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting ABVX GlobeNewswire
Sep-12	Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review ABVX GlobeNewswire
Sep-08	Abivax Presents First Half 2025 Financial Results ABVX GlobeNewswire
Jul-28	Abivax Announces Closing of $747.5 Million Public Offering ABVX GlobeNewswire
Jul-25	Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (637.5M) ABVX GlobeNewswire
Jul-24	Abivax announces trading resumption of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jul-24	Abivax Announces Pricing of $650M (554M) Public Offering of American Depositary Shares ABVX GlobeNewswire
Jul-24	Abivax announces temporary trading halt of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jul-23	Abivax Announces Launch of Public Offering ABVX +586.00% GlobeNewswire
Jul-22	Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis ABVX GlobeNewswire
Jun-11	Abivax Announces Results of its June 6, 2025 Annual General Meeting ABVX -5.72% ABVX -5.39% GlobeNewswire
Jun-02	Abivax Presents First Quarter 2025 Financial Results ABVX +5.48% ABVX +21.89% GlobeNewswire

Abivax

Recent Articles by Abivax

Upgrade your Finviz experience